IP Library › Patent Application 18891542
Patent Application
App. No. 18/891,542

METHOD OF TREATMENT OF ATTENTION DEFICIT/HYPERACTIVITY DISORDER (ADHD)

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/891,542
Abstract

The invention comprises a method for treatment of ADHD or ADHD-related disorders by a pharmaceutical agent exhibiting combined serotonergic or noradrenergic reuptake transporters and monoamine receptor activity.

Claims (17)

1 . A method of treating a patient suffering from at least one mood or affective disorder selected from the group consisting of anxiety, depression, bipolar disorder, obsessive compulsive disorder, Tourette's Syndrome, Post Traumatic Stress Disorder and ADHD, comprising administering to the patient in need thereof a therapeutically effective amount of viloxazine or a pharmaceutically acceptable salt thereof in a formulation.

2 . The method of claim 1 , wherein the disorder comprises a disorder selected from the group consisting of anxiety, depression and bipolar disorder.

3 . The method of claim 1 , wherein the disorder comprises ADHD.

4 . The method of claim 1 , wherein the therapeutically effective amount is from about 20 to about 800 mg a day.

5 . The method of claim 1 , wherein the therapeutically effective amount is from about 100 to about 600 mg a day.

6 . The method of claim 1 , wherein the therapeutically effective amount is from about 150 to about 400 mg a day.

7 . The method of claim 1 , wherein the therapeutically effective amount is from 150 to 300 mg a day.

8 . The method of claim 1 , which provides an improved adverse effect profile.

9 . The method of claim 1 , wherein the patient is a human child.

10 . The method of claim 1 , wherein the disorder comprises anxiety.

11 . The method of claim 1 , wherein the disorder comprises depression.

12 . The method of claim 1 , wherein the disorder comprises bipolar disorder.

13 . The method of claim 1 , wherein the disorder comprises obsessive compulsive disorder.

14 . The method of claim 1 , wherein the disorder comprises Tourette's Syndrome.

15 . The method of claim 1 , wherein the disorder comprises Post Traumatic Stress Disorder.

16 . The method of claim 1 , wherein the administering antagonizes 5-HT7 and 5HT1B receptor activity in the patient.

17 . The method of claim 1 , wherein the patient is a human adult.